树突状细胞疫苗与宫颈癌细胞免疫治疗的新进展  

Advance in Dendritic Cell Vaccine and Cellular Immune Therapy of Cervical Cancer

作　　者：焦庆昉[1,2] 宋方洲[3,2] 易发平[3,2] 

机构地区：[1]重庆医科大学免疫学教研室,重庆400016 [2]重庆医科大学分子医学与肿瘤研究中心,重庆400016 [3]重庆医科大学生物化学与分子生物学教研室,重庆400016

出　　处：《中国生物制品学杂志》2010年第4期445-448,共4页Chinese Journal of Biologicals

基　　金：国家自然科学基金项目(30800945);重庆市科委自然科学基金项目(CSTC;2008BB5225)

摘　　要：宫颈癌是妇科最常见的恶性肿瘤之一,其发病率在女性恶性肿瘤中居第2位。树突状细胞(DC)是机体免疫应答的始动者,以DC为基础的抗肿瘤免疫治疗已成为热点。本文就树突状细胞的抗肿瘤机制及其在宫颈癌免疫治疗中的应用作一综述。Cervical cancer is one of the most common tumors in gynecology, which ranks second on the list of morbidity of malignant tumors in women. Since dendritic cells are the initiator of immune response, DC-based immune therapy of tumor has become a focus of study. This paper reviews the anti-tumor mechanism of DCs as well as the application of DCs in immune therapy of cervical cancer.

关 键 词：树突状细胞 疫苗 宫颈癌 免疫治疗 

分 类 号：R392.11[医药卫生—免疫学] R737.33[医药卫生—基础医学]